3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Renal Cell
17
Gastrointestinal Stromal Tumors
10
Neoplasms
5
Neoplasm Metastasis
4
Multiple Myeloma
4
Kidney Neoplasms
4
Urologic Neoplasms
2
Thyroid Neoplasms
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Osteosarcoma
2
Meningioma
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Kidney Diseases
2
Gastrointestinal Neoplasms
2
Carcinoma, Hepatocellular
2
Carcinoma
2
Adenoma, Islet Cell
2
Uveal Melanoma
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thymoma
1
Stomach Neoplasms
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Rectal Neoplasms
1
Primary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Interventions
asciminib
8
Dasatinib
7
nilotinib
6
Imatinib Mesylate
5
Cyclophosphamide
4
ponatinib
3
fludarabine phosphate
3
bosutinib
3
Whole-Body Irradiation
3
ruxolitinib
2
letermovir
2
Tacrolimus
2
Specimen Handling
2
Peripheral Blood Stem Cell Transplantation
2
Mycophenolic Acid
2
Methotrexate
2
Melphalan
2
Cyclosporine
2
Busulfan
2
venetoclax
1
pembrolizumab
1
pegylated granulocyte colony-stimulating factor
1
decitabine and cedazuridine drug combination
1
Vorinostat
1
Valganciclovir
1
Tyrosine Kinase Inhibitors
1
Therapeutics
1
Stem Cell Transplantation
1
Sirolimus
1
Rituximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Leukemia, Myeloid, Chronic-Phase
×
Sunitinib
×
1 year
×
Clear all
No trials found.